Objective: We present 2 families that were identified with novel mutations in LOXHD1 as a cause of nonprogressive hearing loss. Methods: One thousand three hundred fourteen (1314) Japanese subjects with sensorineural hearing loss from unrelated families were enrolled in the study. Targeted genomic enrichment and massively parallel sequencing of all known nonsyndromic hearing loss genes were performed to identify the genetic cause of hearing loss. Results: Two patients in 1 family affected with homozygous mutation c.879+1G>A in LOXHD1 showed profound congenital hearing loss, whereas 2 patients in another family with compound heterozygous mutations, c.5869G>T (p.E1957X) and c.4480C>T (p.R1494X), showed moderate to severe hearing loss. Conclusion: Mutations in LOXHD1 are extremely rare, and these cases are the first identified in a Japanese population. The genotype-phenotype correlation in LOXHD1 is still unclear. The differences in phenotypes in each patient might be the result of the nature of the mutations or the location on the gene, or be influenced by a genetic modifier.
Introduction
Sensorineural hearing loss (SNHL) associated with autosomal recessive (AR) inheritance is commonly supposed to have a phenotypic feature resulting in severe to profound hearing loss. The most common genetic cause of hearing loss is GJB2, which results in prelingual severe to profound SNHL, and most of these cases present with nonprogressive hearing loss. 1 Several studies have reported that some genetic causes associated with AR inheritance might be naturally occurring progressive hearing loss, such as SLC26A4, CDH23, and MYO3A. The LOXHD1 gene mapped at chromosome 18q12-21 is known to be the cause of DFNB77, a progressive form of autosomal recessive nonsyndromic SNHL. 2 Mutations in LOXHD1 are extremely rare: only 5 reports, 6 pedigrees. LOXHD1 consists of 2211 amino acids that encodes 15 polycystin-1/lipoxygenase/alpha-toxin (PLAT) domains. Each single PLAT domain consists of about 120 amino acids and interacts with the plasma membrane. In a mouse study, Loxhd1 was expressed along the membrane of mature hair cell stereocilia. It played an important role in maintaining normal hair cell function in the cochlea. 2 SNHL, caused by the mutations in LOXHD1, had a phenotypic feature showing progressive hearing loss at mid to high frequencies during childhood. 2, 3 On the other hand, nonprogressive congenital profound hearing loss has been reported as well. 4 Here, we describe 2 families that were identified with novel mutations in LOXHD1 as a cause of progressive hearing loss using massively parallel sequencing (MPS).
Subjects and Methods

Subjects
We recruited 2 groups from a Japanese hearing loss population for this study. All subjects had presumed nonsyndromic SNHL. For each proband, informed consent was obtained to participate in this study, which was approved by the human subjects ethical committee associated with each clinic. Clinical information and blood samples were obtained for each proband and for all consenting affected and unaffected relatives.
In the first group, 1120 Japanese hearing loss patients (autosomal dominant [AD] SNHL, 266; ARSNHL, 600; unknown, 254) from 53 ENT departments nationwide participated. For the second group, 194 Japanese subjects from unrelated families were ascertained through 33 otolaryngology clinics in 28 prefectures across Japan.
Methods
Group 1
Amplicon library preparation. Amplicon libraries were prepared using an Ion AmpliSeq Custom Panel (Applied Biosystems; Life Technologies, Carlsbad California, USA) for 63 genes reported to cause nonsyndromic hearing loss according to the manufacturer's instructions. The detailed protocol was described elsewhere. 5 After preparation, the amplicon libraries were diluted to 20 pM, and equal amounts of 6 libraries for 6 patients were pooled for 1 sequence reaction.
Emulsion polymerase chain reaction (PCR) and sequencing. Emulsion PCR and sequencing were performed according to the manufacturer's instructions. The detailed protocol was described elsewhere. 5 MPS was performed with an Ion Torrent Personal Genome Machine (PGM) system using the Ion PGM 200 Sequencing Kit and Ion 318 Chip (Life Technologies).
Group 2
Targeted genomic enrichment and MPS. Genomic DNA was assessed for quality by gel electrophoresis and spectrophotometry (Nanodrop 1000; Thermo Fisher Scientific, Waltham, Massachusetts, USA; 260/280 ratio of 1.8-2.2) and for quantity by fluorometry (Qubit 2.0 Fluorometer; Life Technologies). Targeted genomic enrichment of all exons of all genes implicated in nonsyndromic SNHL, including nonsyndromic SNHL mimics, was completed as described, targeting 89 genes as part of the OtoSCOPE v5 platform. Libraries were prepared using a modification of the solutionbased Agilent SureSelect target enrichment system (Agilent Technologies, Santa Clara, California). 6 Of the 194 samples, 58 samples were processed manually; the remainder were prepared robotically using the Sciclone NGS Workstation.
In brief, 3 μg of gDNA was randomly fragmented to an average size of 250 bp (Covaris Acoustic Solubilizer; Covaris Inc, Woburn, Massachusetts, USA), fragment ends were repaired, A-tails were added, and sequencing adaptors were ligated before the first amplification. Solid phase reverse immobilization purifications were performed between each enzymatic reaction. Hybridization and capture with RNA baits was followed by a second amplification before pooling for sequencing. Minimal amplification was used-typically 8 cycles for the prehybridization PCR (range, 8-10 cycles) using NEB Phusion HF Master Mix (New England BioLabs Inc, Ipswich, Massachusetts, USA) and 14 cycles for the posthybridization PCR (range, 12-16 cycles) using Agilent Herculase II Fusion DNA Polymerase. All samples were barcoded and multiplexed before sequencing on either an Illumina MiSeq or HiSeq (Illumina Inc, San Diego, California, USA) in pools of 4 to 6 or 48, respectively, using 100-bp paired-end reads.
Base Call and Data Analysis
Group 1. The sequence data were mapped to the human genome sequence (build GRCh37/hg19) with a Torrent Mapping Alignment Program. After the sequence mapping, the DNA variant regions were piled up with Torrent Variant Caller plug-in software. After variant detection, variant effects were analyzed using ANNOVAR software. 7, 8 The missense, nonsense, insertion/deletion, and splicing variants were selected from among the identified variants. Variants were further selected as less than 1% of (1) the 1000 genome database, 9 (2) the 6500 exome variants, 10 (3) the Human Genetic Variation Database (data set for 1208 Japanese exome variants), 11 and (4) the 269 in-house Japanese normal hearing controls.
To predict the pathogenicity of missense variants, the following functional prediction software was used: PhyloP, 12 Sorting Intolerant from Tolerant, 13 Polymorphism Phenotyping (PolyPhen20), 14 LRT, 15 MutationTaster, 16 and GERP++. 17 Candidate mutations were confirmed by Sanger sequencing, and the responsible mutations were identified by segregation analysis using samples from among the patients' family members.
Group 2. Data were analyzed as described using a local installation of the open-source Galaxy software and the following open-source tools: BWA 18 for read mapping, Picard for duplicate removal, GATK 19 for local realignment and variant calling, and NGSRich 20 for enrichment statistics. 21 We reported and annotated variants with custom software.
Variant Confirmation
All pathogenic variants were confirmed by Sanger sequencing and segregation analysis using exon-specific custom primers.
Results
We identified 4 patients, from 2 families, who had causative mutations in LOXHD1 in 1314 hearing loss Japanese.
Case Details
Family No. 963; AH 4029, AH 4028. AH 4029 was a 9
year-old boy. He had not undergone newborn hearing screening. At the age of 6, hearing loss was detected at a school check-up. He had been referred to the Iwate Medical University Hospital, Department of Otolaryngology for further examinations. His tympanic membranes were normal. An auditory brain stem response (ABR) with click stimuli showed bilateral hearing loss that was approximately 40 dBnHL in both ears, and pure-tone audiometry (PTA) showed bilateral moderate sensorineural hearing loss (Figure 1 ). He was promptly fitted with a left hearing aid when he was 7 years, 3 months old. He showed 100% in word scores at the 50 dB sound field threshold. His hearing was unchanged from 6 to 9 years old. He didn't have any episodes of dizziness or vertigo attacks. Computed tomography (CT) findings of the middle and inner ear showed no abnormalities.
AH 4028 was a 3-year-old girl. She was a younger sister of AH 4029, and her parents noticed that she didn't have any intelligible words until she was 1 year, 6 months old. She visited the Iwate Medical University Hospital at the same time that AH 4029 received his check-up. Her bilateral tympanic membranes were normal. A previous ABR test at 2 years of age had shown bilateral severe hearing loss that was approximately 80 dBnHL in both ears, and PTA had also shown bilateral severe SNHL at the age of 3 (Figure 1 ). Her hearing had been unchanged from 3 to 5 years old. She started to wear a right hearing aid when she was 3 years old. CT findings of the middle and inner ear showed no abnormalities. Patient 2059 was a 60-year-old female. She was the younger sister of patient 2061 and was born in 1939. PTA showed bilateral profound SNHL (Figure 2 ). In her medical examination by interview, she also demonstrated congenital nonprogressive hearing loss. She didn't have any episodes of vertigo.
As shown in Figure 2 , the pedigree tree showed consanguineous parental ancestry of patient 2061 and patient 2059 with profound hearing loss. They were both unmarried. We didn't obtain any information about the symptoms of hearing loss during childhood because of World War II.
Mutation Analysis
We identified compound heterozygous mutations, c.5869G>T, p.E1957X and c.4480C>T, p.R1494X in the LOXHD1 gene in 2 patients from family No. 963.
We also identified homozygous splice site mutations: c.879+1G>A in the LOXHD1 gene in 2 patients from family No. 143.
Discussion
We identified causative compound heterozygous p.R1494X and p.E1957X and homozygous c.879+1G>A mutations in the LOXHD1 gene. These are the first cases found in the Japanese population.
As shown in Table 1 , we summarized the mutations in LOXHD1 that have been previously reported. The mutations of p.E1957X and c.879+1G>A were novel, and p.R1494X had been reported in an American family. 22 LOXHD1 is expressed along the plasma membrane of the stereocillia. It is considered that LOXHD1 may couple the plasma membrane to the underlying F-actin cytoskeleton. Although stereocilliary development was unaffected in a mouse model (samba mouse), hair cell function was disturbed and hair cells eventually degenerated. 2 In this study, affected individuals in family No. 143 showed profound congenital SNHL, but affected individuals in family No. 963 showed different degrees of SNHL; hearing loss in AH 4028 was about 30 dB more severe than in her older sibling. Vozzi et al 3 reported 3 patients, in a consanguineous family, who had early-onset progressive SNHL, which differed in degree in spite of having the same genotype, homozygous nonsense alleles (c.1588G>T, p.E530X). On the other hand, nonprogressive congenital SNHL was also reported in other homozygous nonsense alleles (c.4714C>T, p.R1572X). 4 In samba mice, a homozygous missense mutation in Loxhd1 caused profound deafness shortly after birth. Nevertheless, homozygous nonsense mutations in Loxhd1 caused progressive hearing loss. 2 The cases in family No. 143 had splice site mutations and were totally deafened by their sixties. It is possible that their hearing deteriorated in childhood, resulting in profound hearing loss at a younger age. The genotype-phenotype correlation in LOXHD1 is still unclear. The differences in phenotypes in each affected individual might be the result of the nature of the mutations and the location on the gene, or result from agenetic modifier. 23 Two affected individuals in family No. 963 were fitted with hearing aids, and both of them were able to benefit from them. If their hearing loss progresses in future, a cochlear implant could be considered for them to acquire hearing ability. Eppsteiner et al 22 Hearing threshold (dB) III-1 III-2
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c.5869G>T c.4480C>T Affected individuals in family No. 963 and family No. 143 had no episodes of dizziness or vertigo attacks. No vestibular dysfunction is yet to be reported. Grillet et al 2 described Loxhd1 expression was detected in the stereocillia of vestibular hair cells. However, under immunofluorescence microscopy, the expression level in vestibular hair cells was much weaker than that in cochlear hair cells. 2 Thus, LOXHD1 might not associate with the vestibular system.
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Mutations in LOXHD1 have been reported to be responsible for late-onset Fuchs corneal dystrophy (FCD). 24 FCD is a genetic disorder of the corneal endothelium and is the most common cause of corneal transplantation. Recently, Stehouwer et al 25 reported that the rate of hearing disability in the FCD group was higher than that in the control group. This suggested an association between FCD and hearing loss. It is important that patients with hearing loss caused by LOXHD1 have an ophthalmology check-up. Furthermore, FCD cases with hearing loss should be screened for LOXHD1 mutation. These phenotypic features are important for genetic counseling. Further following examination should be necessary for the relevance to hearing loss and FCD caused by LOXHD1 mutations. In summary, we analyzed 1314 Japanese and identified 4 patients, and 3 mutations in LOXHD1. It seems extremely rare, 0.30% in Japanese hearing loss patients. Candidate gene testing is not applicable for such rare genes. MPS makes it possible to detect rare genes like LOXHD1.
